NARDIL (phenelzine sulfate) by Pfizer is clinical pharmacology monoamine oxidase is a complex enzyme system, widely distributed throughout the body. First approved in 1961.
Drug data last refreshed 8h ago · AI intelligence enriched 5d ago
NARDIL (phenelzine sulfate) is a monoamine oxidase (MAO) inhibitor approved in 1961 for depression and other psychiatric conditions. It works by inhibiting MAO enzyme activity, increasing monoamine neurotransmitters in the central nervous system. The exact mechanism linking MAO inhibition to clinical efficacy remains incompletely understood.
Limited commercial activity with approaching loss of exclusivity signals a mature, small-footprint franchise with minimal team expansion.
CLINICAL PHARMACOLOGY Monoamine oxidase is a complex enzyme system, widely distributed throughout the body. Drugs that inhibit monoamine oxidase in the laboratory are associated with a number of clinical effects. Thus, it is unknown whether MAO inhibition per se, other pharmacologic actions, or an…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
Worked on NARDIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on NARDIL offers limited career growth and visibility due to its mature lifecycle and minimal market footprint (278 claims, $116K spending in 2023). Positions are predominantly defensive, focused on maintaining an aging franchise rather than innovation or expansion.